Home › Type 1 Diabetes › NCT06976619
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People
Who can join
Ages 25 to 70 · All sexes
Full eligibility criteria
Inclusion Criteria: * Type 1 or type 2 diabetes treated with insulin Exclusion Criteria: 1. Age \< 25 or \> 70 years. 2. HbA1c \> 10.0% 3. For female subjects: positive pregnancy test at the time of enrollment or study 4. History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy. 5. Prior use of GLP-1 receptor agonists in the previous year. 6. Active systemic illness or malignancy. 7. Symptomatic macrovascular or microvascular disease.
About the study
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ in Type 1 diabetes (T1DM) compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.
What is being tested
- Liraglutide Pen Injector (drug)
- Saline Injections (other)
Sponsor: Mayo Clinic · Participants: 60 · Started: Oct 3, 2025
Contact the study team
- Adrian Vella, MD · Phone: 507-255-6515
Official record on ClinicalTrials.gov — NCT06976619
Locations in the U.S.
| Minnesota | Mayo Clinic in Rochester, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.